No abstract

No abstract

Introduction: Aluminium studied as a potentially toxic metal and is commonly found in earth's crust. Aluminium toxicity may lead to: aluminium-induced bone disease, microcytic anaemia and neurological manifestation, such conditions more particular seen in patients with chronic renal failure and principally patients on haemodialysis. Objectives: The objective of our study was to measure a serum aluminium levels in patients undergoing haemodialysis at tertiary care hospital, Bengaluru. Materials and Methods: This was a prospective study, conducted on 50 patients who were on maintenance haemodialysis for more than 6 months. 5 ml of the blood was drawn from the antecubital vein from the patient before haemodialysis process. Collected blood samples were estimated for aluminium levels by GFAAS. The dialysis fluid and RO water were also tested similarly for presence of aluminium to correlate the possible contamination. Results: The results were; 6(12%) patients had serum aluminium levels within baseline i.e. <20μg/L, 18(36%) patients had serum aluminium levels between 21-60μg/L and 26 (52%) of the patients had serum aluminium levels above 60μg/L. The aluminium content varied in the dialysate fluid reaching greater than the standard safety limit. Conclusion: In our study we found that aluminium toxicity is a serious problem in patients undergoing haemodialysis. Patients performing haemodialysis for longer period showed higher level of aluminium. Patients age of 50 years and on haemodialysis for duration 3 years need to be monitored carefully for aluminium toxicity. The major source of elevated serum aluminium in our study participants appears to be dialysate fluid, use of aluminium utensils, OTC products and food habits of consult patients.

tiple logistic regression models. As result of the very high correlation amongst MLHFQ global score, physical and emotional dimensions we conducted three models, one for each MLHFQ dimension. RESULTS: The mean (SD) age of patients was 76.8 (10.7), and there were a 57.6% of men. At one year we observed 114 deaths (20.5%). Charlson index was divided into three categories, 0-1 (27.9%), 2-3 (38.8%) and greater than 3 (33.3%). The three multivariate models showed that both the total score and MLHFQ subscales, physical and emotional, were significantly associated with the likelihood of 1-year mortality, with an OR (IC95%) of 1.02 (1.01-1.03), 1.05 (1.02-1.08), and 1.04 (1-1.08), respectively. Further, all the adjustment variables resulted significant in the models, showing a higher risk of mortality as the Charlson index category and age increased, and within men. CONCLUSIONS: HRQoL as measured by MLHFQ can be considered as an independent predictor of mortality at 1-year.

Guillain-Barré Syndrome (GBS) is a rare autoimmune disorder associated with demyelinating polyneuropathy requiring early diagnosis and accurate treatment. From birth to 30 years, the annual incidence is fairly uniform at 1.3 to 1.9 per 100,000. Clinical hallmarks include symmetrical flaccid muscle paresis and areflexia in the presence of an increased cerebrospinal fluid protein and electrophysiologic studies demonstrating demyelination. A case of 29 year old female presenting to a tertiary care hospital with GB syndrome and hypothyroidism is described. The significance of an appropriate diagnosis by the physician and subsequent management by the clinical staff is reviewed.